Therapeutic peptides: the devil is in the details the next generation of peptides pharmaceutical may push manufacturing processes beyond their limits

Bio/Technology

Volumn 14, Issue 1, 1996, Pages 28-31

  Kelley, William S ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0006614201     PISSN: 0733222X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. IMS America Ltd. 1995. Reported in HedAdfJen-s 14 (5):23.
2. Verlander, M., Bachern, CA, personal communication.
3. Naude, A. 1993. Peplides-Wailing far Harvest. Chemical Marketing Reporter, SR 14, Intermediates '93.
4. Neely, M., Mallinckrodt Chemicals, personal communication
5. Du Vigneau, V., et al. 1954. JACS 76:3115-3121.
6. Jones, J. 1992. Amino Acid and Peptide Synthesis, New York: Oxford University Press, p. 60.
7. Jones, D., ProPeptide SNPE; personal communication.
8. Persichette, R.A., et al. 1995. JACS 117:2732-2737.
9. BioScan, Vol. 8., February 1995.
10. Point of View Report. 1993. Peptide Therapeutics...Business Opportunities and Threats.